secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058230
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023
-------------------------------------------------------------------------------

- Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.
- Net loss $17.9M in Q3 2023 vs $16.5M in Q3 2022; R&D expenses rose to $13.2M from $7.8M.
- Phase 2b study of MM-120 in GAD (198 participants) topline results expected in Q4 2023.
- Phase 2a proof-of-concept study of MM-120 in ADHD (53 participants) topline data expected Q1 2024.
- Initiation of Phase 1 study of MM-402 for ASD expected in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/0000950170-23-058230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/mnmd-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer